Gubra

356 DKK

-4.3 %

Less than 1K followers

GUBRA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-4.3%

-29.92%

-46.87%

-42.95%

-18.54%

+25.35%

+223.64%

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.

Market cap

5.82B DKK

Turnover

14.6M DKK

Revenue

265.74M

EBIT %

-18.82 %

P/E

Dividend yield-%

Coverage

Disclaimer

Latest research

Latest analysis report

Released: 17.03.2025

Financial calendar

21.8

2025

Interim report Q2'25

27.2

2026

Annual report '25

All

Research

Webcasts

Press releases

ShowingAll content types

Analyst Comment4/16/2025, 7:05 AM

Dagens aktienyheder 16/04: Gubra og BioPorto A/S

Dagens aktienyheder med Gubra og BioPorto A/S

Gubra BioPorto

Webcast5/9/2025, 11:00 AM

Gubra – Præsentation af Q1 2025

Mød og stil spørgsmål til Gubra’s ledelse - CEO Henrik Blou og CFO Kristian Borbos - fredag d. 9. maj kl. 13.00. Fokus for dette event er udviklingen i 1. kvartal 2025. Et kvartal der bød på flere spændende begivenheder. Selskabet har opdateret sin strategi med mere fokus på D&P forretningsområdet og indgik en partneraftale med AbbVie på GUBamy, som er i fase 1a.

Gubra

Press release4/3/2025, 2:17 PM

Gubra Welcomes New Board Members at 2025 AGM

Gubra

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Regulatory press release4/3/2025, 12:06 PM

Course of Gubra A/S' Annual General Meeting 2025

Gubra

Analyst Comment4/2/2025, 7:14 AM by

Claus Thestrup, Michael Friis, Rasmus Køjborg

Dagens aktienyheder 02/04: Gubra, Pharma Equity Group, Wirtek, ExpreS2ion Biotechnologies og Spar Nord Bank

Dagens aktienyheder med Gubra, Pharma Equity Group, Wirtek, ExpreS2ion Biotechnologies og Spar Nord Bank

Gubra Pharma Equity Group Wirtek ExpreS2ion Biotech Holding Spar Nord Bank

Regulatory press release4/1/2025, 2:52 PM

Successful Transaction Closure of License Agreement

Gubra

Analyst Comment4/1/2025, 10:08 AM by

Claus Thestrup, Philip Coombes

Gubra: Offentliggør positive data fra fase 1 MAD-resultater for GUBamy

Gubra

Regulatory press release4/1/2025, 6:45 AM

Gubra announces positive GUBamy Phase 1 interim MAD results

Gubra

Analyst Comment3/31/2025, 7:10 AM by

Claus Thestrup, Rasmus Køjborg

Dagens aktienyheder 31/03: Gubra, SP Group og Aktier med Friis.

Dagens aktienyheder med Gubra, SP Group og Aktier med Friis.

Gubra SP Group

Regulatory press release3/28/2025, 9:32 PM

Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra

Gubra

Analyst Comment3/26/2025, 8:05 AM

Dagens aktienyheder 26/03: Gubra og Flügger group A/S

Dagens aktienyheder med Gubra og Flügger group A/S

Gubra Flügger Group

Gubra: Understanding valuation (PoS) post Abbvie deal

Video3/26/2025, 7:55 AM by

Philip Coombes, Claus Thestrup

Gubra: Understanding valuation (PoS) post Abbvie deal

The company combines the best of both worlds – a fast-growing, cash-generating CRO business serving top pharma companies and a high-risk, high-reward drug discovery pipeline. A landmark partnership with AbbVie, which includes upfront payments of USD 350m for its obesity drug, GUBamy, highlights its innovation potential. With advanced AI platforms and new candidates like UCN2 in the pipeline, Gubra is positioned at the frontier of biotech. Watch the video to understand what the market is pricing in – and what could unlock further development?

Gubra